Wilmington Savings Fund Society FSB Has $550,000 Position in Alnylam Pharmaceuticals, Inc. $ALNY

Wilmington Savings Fund Society FSB lifted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 53.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,686 shares of the biopharmaceutical company’s stock after purchasing an additional 588 shares during the quarter. Wilmington Savings Fund Society FSB’s holdings in Alnylam Pharmaceuticals were worth $550,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. SVB Wealth LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth about $27,000. Bessemer Group Inc. raised its position in shares of Alnylam Pharmaceuticals by 176.9% during the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 69 shares during the period. Ameritas Advisory Services LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth about $42,000. Washington Trust Advisors Inc. raised its position in shares of Alnylam Pharmaceuticals by 53.5% during the first quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 61 shares during the period. Finally, Steph & Co. bought a new position in shares of Alnylam Pharmaceuticals during the second quarter worth about $60,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insider Buying and Selling

In other news, EVP Tolga Tanguler sold 1,405 shares of the firm’s stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total value of $635,130.25. Following the completion of the sale, the executive vice president directly owned 27,438 shares of the company’s stock, valued at $12,403,347.90. This trade represents a 4.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Pushkal Garg sold 3,022 shares of the firm’s stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $451.48, for a total value of $1,364,372.56. Following the completion of the sale, the executive vice president directly owned 20,221 shares of the company’s stock, valued at approximately $9,129,377.08. The trade was a 13.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 98,144 shares of company stock valued at $44,160,261. Insiders own 1.50% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on ALNY shares. Wall Street Zen downgraded Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Sunday, October 12th. Needham & Company LLC increased their price objective on Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the stock a “buy” rating in a report on Thursday, July 31st. Oppenheimer upgraded Alnylam Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $490.00 price objective for the company in a report on Monday, August 4th. Raymond James Financial started coverage on Alnylam Pharmaceuticals in a report on Wednesday, July 30th. They set an “outperform” rating and a $370.00 price objective for the company. Finally, JPMorgan Chase & Co. decreased their price objective on Alnylam Pharmaceuticals from $475.00 to $473.00 and set an “overweight” rating for the company in a report on Monday, October 13th. Twenty-four analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $463.08.

Alnylam Pharmaceuticals Stock Up 0.1%

ALNY stock opened at $481.67 on Friday. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10. The business has a 50 day moving average price of $455.90 and a two-hundred day moving average price of $352.20. The company has a market cap of $63.14 billion, a price-to-earnings ratio of -195.01 and a beta of 0.36. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $492.62.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.86. The firm had revenue of $773.69 million during the quarter, compared to the consensus estimate of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The business’s revenue was up 17.3% compared to the same quarter last year. During the same period last year, the company earned ($0.13) earnings per share. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.